CLINICAL TRIALS PROFILE FOR VELBAN

All Clinical Trials for Velban

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002855 ↗	Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 3	1996-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
NCT00002855 ↗	Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer	Completed	M.D. Anderson Cancer Center	Phase 3	1996-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
NCT00002882 ↗	Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma	Completed	National Cancer Institute (NCI)	Phase 3	1995-11-01	RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. It is not yet known whether interferon alfa plus combination chemotherapy and interleukin-2 is more effective than interferon alfa alone in treating patients with melanoma. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without combination chemotherapy plus interleukin-2 in treating patients with melanoma.
NCT00002882 ↗	Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma	Completed	M.D. Anderson Cancer Center	Phase 3	1995-11-01	RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. It is not yet known whether interferon alfa plus combination chemotherapy and interleukin-2 is more effective than interferon alfa alone in treating patients with melanoma. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without combination chemotherapy plus interleukin-2 in treating patients with melanoma.
NCT00003019 ↗	Vinblastine and Methotrexate in Treating Children With Desmoid Tumors	Completed	Children's Cancer Group	Phase 2	1997-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with vinblastine and methotrexate in treating children who have desmoid tumors that are recurrent or untreatable with surgery or radiation therapy.
NCT00003019 ↗	Vinblastine and Methotrexate in Treating Children With Desmoid Tumors	Completed	National Cancer Institute (NCI)	Phase 2	1997-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with vinblastine and methotrexate in treating children who have desmoid tumors that are recurrent or untreatable with surgery or radiation therapy.
NCT00003019 ↗	Vinblastine and Methotrexate in Treating Children With Desmoid Tumors	Completed	Children's Oncology Group	Phase 2	1997-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with vinblastine and methotrexate in treating children who have desmoid tumors that are recurrent or untreatable with surgery or radiation therapy.

Clinical Trial Conditions for Velban

Condition Name

Condition Name for Velban
Intervention	Trials
Lymphoma	5
Prostate Cancer	3
Classic Hodgkin Lymphoma	3
Transitional Cell Carcinoma of the Bladder	2

Condition MeSH

Condition MeSH for Velban
Intervention	Trials
Hodgkin Disease	14
Lymphoma	10
Carcinoma, Transitional Cell	7
Urinary Bladder Neoplasms	6

Clinical Trial Locations for Velban

Trials by Country

Trials by Country for Velban
Location	Trials
United States	326
Canada	14
Australia	2
South Africa	1
Puerto Rico	1

Trials by US State

Trials by US State for Velban
Location	Trials
Texas	20
Illinois	13
California	13
Ohio	10
Iowa	10

Clinical Trial Progress for Velban

Clinical Trial Phase

Clinical Trial Phase for Velban
Clinical Trial Phase	Trials
Phase 3	10
Phase 2	22
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for Velban
Clinical Trial Phase	Trials
Completed	17
Recruiting	6
Active, not recruiting	5

Clinical Trial Sponsors for Velban

Sponsor Name

Sponsor Name for Velban
Sponsor	Trials
National Cancer Institute (NCI)	22
M.D. Anderson Cancer Center	10
Northwestern University	2

Sponsor Type

Sponsor Type for Velban
Sponsor	Trials
Other	38
NIH	22
Industry	12

Clinical Trials, Market Analysis, and Projections for Velban (Vinblastine)

Introduction

Vinblastine, commonly known by its brand name Velban, is a chemotherapeutic agent used in the treatment of various cancers, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, and other malignancies. This article will delve into recent clinical trial updates, market analysis, and projections related to Vinblastine.

Clinical Trials Update

Recent Trials and Outcomes

A significant clinical trial update involves the use of Vinblastine in combination with other drugs for the treatment of early-stage unfavorable classical Hodgkin lymphoma (HL). The NIVAHL trial, a randomized phase II study, combined Vinblastine with Doxorubicin, Dacarbazine, and Nivolumab, followed by involved-site radiotherapy. This regimen resulted in high complete remission rates and an unprecedented 1-year progression-free survival rate. After a median follow-up of 41 months, the overall survival was 100% in both treatment groups, and the progression-free survival was 98% and 100% in the sequential and concomitant treatment groups, respectively[1].

Safety and Efficacy

The long-term safety analysis of the NIVAHL trial showed favorable outcomes. There were no survival events since the primary analysis, and patients maintained good pulmonary and cardiac function. Hypothyroidism requiring long-term medication was observed in 15% of patients, predominantly females. No second primary malignancies or corticosteroid treatments were necessary at the last follow-up. Patient-reported quality-of-life scores improved over time, indicating a relatively favorable safety profile and high efficacy of this therapeutic approach[1].

Market Analysis

Global Clinical Trials Market

The global clinical trials market, which includes trials involving Vinblastine, is projected to grow significantly. From $61.58 billion in 2024, the market is expected to reach $106.78 billion by 2032, at a Compound Annual Growth Rate (CAGR) of 7.1%. This growth is driven by the increasing prevalence of chronic diseases and the need for new treatments[3].

Regional Market Share

North America and Europe hold substantial market shares in the clinical trials sector. North America generated $27.65 billion in revenue in 2023, while Europe is expected to witness stagnant growth during the forecast period. The Asia Pacific region, however, is expected to expand at the fastest CAGR due to the increasing prevalence of infectious and chronic diseases[3].

Market Projections for Vinblastine

Demand and Usage

The demand for Vinblastine is expected to remain strong due to its efficacy in treating various types of cancer. As the global clinical trials market grows, so does the potential for increased usage of Vinblastine in combination therapies. The integration of new technologies, such as gen AI, in the life sciences industry is likely to enhance the efficiency and effectiveness of drug development, including Vinblastine-based treatments[2].

Competitive Landscape

The life sciences industry is highly competitive, with multiple companies investing heavily in research and development (R&D). The focus on personalized medicine, driven by advances in genomics and biomarkers, is expected to improve treatment outcomes and reduce side effects. Companies are exploring various initiatives to enhance their market positions, which could impact the competitive landscape for Vinblastine[2].

Economic and Policy Factors

Economic forecasts for 2025 suggest continued global economic growth, though with potential inflationary pressures. Supply-side factors, such as labor productivity and available labor, are expected to drive growth. However, policy risks, including trade tariffs and immigration policies, could offset these gains. These economic dynamics may influence the pricing and reimbursement strategies for drugs like Vinblastine[5].

Technological Advancements and Impact

Digital Transformation and AI

The life sciences industry is undergoing significant digital transformation, with a focus on gen AI and other digital innovations. These technologies are expected to reduce costs in R&D, streamline operations, and enhance patient outcomes. For Vinblastine, the integration of AI could optimize treatment protocols and improve the efficiency of clinical trials[2].

Precision Medicine

Advances in precision medicine, particularly in genomics and biomarkers, are revolutionizing cancer treatment. Trials like the NIVAHL study demonstrate the potential of combining immunotherapy with traditional chemotherapy, such as Vinblastine, to achieve better outcomes. This precision approach could further solidify Vinblastine's place in cancer treatment regimens[2].

Patient Outcomes and Quality of Life

Quality of Life Studies

The NIVAHL trial highlighted improvements in patient-reported quality-of-life scores over time. This is a critical aspect of cancer treatment, as it reflects not only the efficacy of the treatment but also its impact on the patient's well-being. As treatments involving Vinblastine continue to evolve, maintaining or improving quality of life will remain a key focus[1].

Long-Term Safety

Long-term safety data from clinical trials are crucial for understanding the sustained impact of treatments. The favorable safety profile observed in the NIVAHL trial, including minimal long-term adverse effects, supports the continued use of Vinblastine in combination therapies[1].

Key Takeaways

• High Efficacy: Vinblastine, when used in combination with other drugs like Nivolumab, Doxorubicin, and Dacarbazine, shows high complete remission rates and excellent progression-free survival.
• Favorable Safety Profile: Long-term safety analysis indicates minimal adverse effects, with good pulmonary and cardiac function maintained.
• Market Growth: The global clinical trials market is expected to grow significantly, driven by the increasing prevalence of chronic diseases.
• Technological Advancements: Digital transformation and AI are likely to enhance the efficiency and effectiveness of Vinblastine-based treatments.
• Precision Medicine: Advances in genomics and biomarkers are improving treatment outcomes and reducing side effects.

FAQs

What are the recent clinical trial outcomes for Vinblastine in treating Hodgkin's lymphoma?

Recent trials, such as the NIVAHL study, have shown high complete remission rates and excellent progression-free survival when Vinblastine is combined with Nivolumab, Doxorubicin, and Dacarbazine, followed by radiotherapy[1].

How is the global clinical trials market expected to grow?

The global clinical trials market is projected to grow from $61.58 billion in 2024 to $106.78 billion by 2032, at a CAGR of 7.1%, driven by the increasing prevalence of chronic diseases[3].

What role does digital transformation play in the life sciences industry?

Digital transformation, particularly through gen AI, is expected to reduce costs, streamline operations, and enhance patient outcomes. It could optimize treatment protocols and improve the efficiency of clinical trials involving Vinblastine[2].

How does precision medicine impact the use of Vinblastine?

Precision medicine advances, such as those in genomics and biomarkers, are improving treatment outcomes by allowing for more targeted and effective use of Vinblastine in combination therapies[2].

What are the long-term safety implications of using Vinblastine in cancer treatment?

Long-term safety data indicate minimal adverse effects, with patients maintaining good pulmonary and cardiac function. Hypothyroidism is a notable side effect, but overall, the safety profile is favorable[1].

Sources

1. Clinical Trial Updates: "Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Classical Hodgkin Lymphoma" - PubMed.
2. 2025 Life Sciences Outlook: Deloitte Insights.
3. Clinical Trials Market Report: Fortune Business Insights.
4. DCTD Newsletter: National Cancer Institute.
5. Economic and Market Outlook 2025: Vanguard.